Purpose

Longwood Fund is a healthcare venture capital firm that founds, manages, and builds healthcare companies.

Longwood's mission is to identify technologies and to found companies that will advance new therapeutics that can not only make a difference in the lives of patients worldwide, but also create significant value for investors. This is achieved by leveraging the management team’s history of successful healthcare company formation and operational leadership. Longwood’s portfolio includes Alnara Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2010 for $180 million cash upfront and a $200 million earn-out, Verastem, Inc. (NASDAQ: VSTM), a healthcare company focused on discovering and developing novel drugs that selectively target cancer stem cells, OvaScience, Inc. (NASDAQ: OVAS), a healthcare company focused on translating new science into fertility treatments for women, IlluminOss Medical, a device company dedicated to bringing minimally invasive solutions for the stabilization and treatment of bone fractures to market, PTC Therapeutics, a healthcare company focused on the discovery and commercialization of orally active small molecule therapeutics, Mitokyne, Inc., a healthcare company focused on mitochondria-related drug discovery and development, Calithera Biosciences, Inc., a healthcare company that’s discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival, and Flex Pharma, a healthcare company, focused on developing clinically proven treatments for muscle cramps and spasms. Members of the Longwood team have founded and built several successful healthcare companies including Momenta Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Sirtris Pharmaceuticals, Inc.